Leadership Transition at Pulmonx Corporation
In an exciting development at Pulmonx Corporation (NASDAQ: LUNG), the company has announced the reappointment of Glen French as President and Chief Executive Officer. This change is effective immediately and signifies a renewed commitment to the company's mission in lung health. French, who previously served as CEO, brings over 25 years of experience in interventional pulmonology, making him an ideal choice to lead this innovative organization into its next chapter.
Derrick Sung Takes on New Role
Derrick Sung, a former Chief Financial Officer of Pulmonx, has been appointed as the Chief Operating Officer and Chief Financial Officer. This strategic move is expected to leverage Sung's financial expertise and operational acumen to further enhance Pulmonx's growth trajectory and operational efficiency.
Resignation of Key Executives
As part of this leadership reshuffle, Steve Williamson and Mehul Joshi have resigned from their respective roles. Both individuals will, however, remain in advisory capacities until December 1, 2025, facilitating a smooth transition. Their departures are amicable, with no reported disagreements regarding company operations or policies.
Preliminary Revenue Insights
Amidst the leadership changes, Pulmonx has also shared preliminary, unaudited revenue figures for the third quarter of 2025, estimating total revenue at approximately $21.5 million. This promising number reflects growing demand for the company’s innovative lung treatments and therapies.
Upcoming Earnings Call Details
To discuss these updates, Pulmonx will hold an earnings call on November 12, 2025. The call will be at 1:30 p.m. PT / 4:30 p.m. ET, where management will outline third-quarter financial results along with insights on the recent leadership transition. Interested stakeholders can expect a live webcast accessible from the Investor Relations section of Pulmonx’s website.
Looking Ahead
With Glen French at the helm once again, there is palpable optimism about Pulmonx's focus on innovation and the enhancement of patient care in the realm of chronic obstructive pulmonary disease (COPD). The company's flagship product, the Zephyr Endobronchial Valve, continues to be a cornerstone of their offerings and reflects their commitment to advancing respiratory health.
Commitment to Stakeholders
In statements reflecting the company's strategic directions, Dana G. Mead, Jr., Chairperson of the Board, expressed confidence that Glen and Derrick's return to leadership roles will inject the company with renewed vigor. The management team aims to prioritize value creation for all stakeholders, ensuring that Pulmonx remains at the forefront of lung disease treatment.
Frequently Asked Questions
What prompted the leadership change at Pulmonx Corporation?
Glen French was reappointed to bring experienced leadership back to the company amidst significant developments and to foster growth.
What is Derrick Sung's new role?
Derrick Sung has been appointed Chief Operating Officer and Chief Financial Officer, enhancing Pulmonx's operational and financial strengths.
How much revenue did Pulmonx generate in Q3 2025?
Preliminary estimates suggest that Pulmonx generated approximately $21.5 million in revenue for the third quarter of 2025.
When is the earnings call scheduled?
The earnings call is set for November 12, 2025, at 1:30 PM PT / 4:30 PM ET to discuss financial results and management transitions.
What are the future prospects for Pulmonx?
With a strong leadership team and an innovative product lineup, Pulmonx aims to enhance patient care and strengthen its market position in lung health.
